en · de · es · fr · pt
creatine-notes.peptides6908.com › Info › Molecular Background And Naming — Evidence Review

Molecular Background And Naming — Evidence Review

By Editorial Desk · published 2026-02-07 · last reviewed 2026-03-21 · Info

Everything below concerns Drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight (no linker)~3.37 kDaCalculated from peptide sequence
Molecular weight (with linker)~3.65 kDaIncludes albumin-binding moiety
AppearanceWhite to off-white powderTypically lyophilized
SolubilitySoluble in waterAlso dissolves in aqueous buffers
Common synonymsModified GRF(1-29), DAC:GRFUsage varies by source

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Related pages on this site

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Background from the literature

==== Comeback attempt and retirement (2006) ==== On January 23, 2006, the Astros indicated that they would file a claim on an insurance policy on Bagwell's health to collect approximately $15.6 million of the $17 million in salary owed to him for the 2006 season. Days earlier, orthopedic surgeon Dr. James Andrews had performed a physical examination on Bagwell and determined that he had become "completely disabled" and was unable to play baseball again. Because of the language of the policy, the Astros could not release him without losing their settlement, nor could he take the field. The decision effectively eliminated his chances of playing again in the Major Leagues. On March 28, Cigna rejected the claim, contending that because Bagwell had played during 2005 World Series he could not have become more disabled during the period of baseball inactivity characteristic of the offseason. Nonetheless, Bagwell still reported to spring training hoping he could contribute in some way during the upcoming 2006 campaign, and to test the injured shoulder. His mere presence in camp put the Astros' insurance claim into further question, creating an awkward situation between the player and the team. He appeared in 14 spring training games, batting .219 with one double. He never had to make any difficult throws that would place notable stress on his shoulder, as the other infielders shifted toward him. As expected, the Astros put him on the 15-day disabled list in late March with bone spurs in the shoulder.

During World War II the Germans experimented with the idea of the schnorchel (snorkel) from captured Dutch submarines but did not see the need for them until rather late in the war. The schnorchel is a retractable pipe that supplies air to the diesel engines while submerged at periscope depth, allowing the boat to cruise and recharge its batteries while maintaining a degree of stealth. Especially as first implemented however, it turned out to be far from a perfect solution. There were problems with the device's valve sticking shut or closing as it dunked in rough weather. Since the system used the entire pressure hull as a buffer, the diesels would instantaneously suck huge volumes of air from the boat's compartments, and the crew often suffered painful ear injuries. Speed was limited to 8 knots (15 km/h), lest the device snap from stress. The schnorchel also created noise that made the boat easier to detect with sonar, yet more difficult for the on-board sonar to detect signals from other vessels. Finally, allied radar eventually became sufficiently advanced that the schnorchel mast could be detected beyond visual range. In clear weather, diesel exhausts can be seen on the surface to a distance of about three miles, while "periscope feather" (the wave created by the snorkel or periscope moving through the water) is visible from far off in calm sea conditions. Modern radar is also capable of detecting a snorkel in calm sea conditions.

=== Surface Tension Uncut and On a Rail Uncut === In Surface Tension Uncut, the "Surface Tension" chapter was expanded to include certain areas of the original game that were not released along with the remake, as the developer had left before his work was finished. The developer, Chon Kemp, known on the Black Mesa: Community Forums by the pseudonym TextFAMGUY1, also modified the "On a Rail" chapter to include the areas cut from Black Mesa to make gameplay less tedious. Kemp was later hired by Crowbar Collective to remake Surface Tension Uncut for the Steam release, while the uncut version of "On a Rail" was published on the Steam Workshop.

Sources: en.wikipedia.org

Reference notes

In 1984, he co-founded Lee Scientific to develop and market supercritical fluid chromatographic instrumentation and, in 1991, he co-founded Sensar Corporation to develop and market unique time-of-flight mass spectrometry instrumentation. He is a co-founder of Torion Technologies, which markets a hand-portable gas chromatography-mass spectrometry system. He is listed as a co-inventor on twenty issued patents.

A problem with resonant cavities is that a high finesse cavity has very narrow cavity modes, often in the low kHz range (the width of the cavity modes is given by FSR/F, where FSR is the free-spectral range of the cavity, which is given by c/2L, where c is the speed of light and L is the cavity length). Since cw lasers often have free-running linewidths in the MHz range, and pulsed even larger, it is non-trivial to couple laser light effectively into a high finesse cavity. The most important resonant CEAS techniques are cavity ring-down spectrometry (CRDS), integrated cavity output spectroscopy (ICOS) or cavity enhanced absorption spectroscopy (CEAS), phase-shift cavity ring-down spectroscopy (PS-CRDS) and Continuous wave Cavity Enhanced Absorption Spectrometry (cw-CEAS), either with optical locking, referred to as (OF-CEAS), as has been demonstrated Romanini et al. or by electronic locking., as for example is done in the Noise-Immune Cavity-Enhanced Optical-Heterodyne Molecular Spectroscopy (NICE-OHMS) technique. or combination of frequency modulation and optical feedback locking CEAS, referred to as (FM-OF-CEAS). The most important non-resonant CEAS techniques are off-axis ICOS (OA-ICOS) or off-axis CEAS (OA-CEAS), wavelength modulation off-axis CEAS (WM-OA-CEAS), off-axis phase-shift cavity enhanced absorption spectroscopy (off-axis PS-CEAS). These resonant and non-resonant cavity enhanced absorption techniques have so far not been used that frequently with TDLAS. However, since the field is developing fast, they will presumably be more used with TDLAS in the future.

=== Generic names === Drostanolone propionate is the generic name of the drug and its BANMTooltip British Approved Name, while dromostanolone propionate is the USANTooltip United States Adopted Name and USPTooltip United States Pharmacopeia; there is no INNTooltip International Nonproprietary Name for this form. The generic name of the unesterified form of the drug is drostanolone or dromostanolone and the former is its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française while there is no USANTooltip United States Adopted Name.

Sources: en.wikipedia.org

Notes from published material

38 Mod 3): Nimitz-class aircraft carrier, Arleigh Burke-class destroyer, Ticonderoga-class cruiser, Oliver Hazard Perry-class frigate, Wasp-class amphibious assault ship, Tarawa-class amphibious assault ship, Whidbey Island-class dock landing ship, Harpers Ferry-class dock landing ship, Austin-class amphibious transport dock, Blue Ridge-class command ship, Cyclone-class patrol ship, Mark VI patrol boat Marine Corps: LAV-25 Coast Guard (Mk. 38 Mod 0, Mk. 38 Mod 2 and Mk. 38 Mod 3): Reliance-class cutter, Hamilton-class cutter, Sentinel-class cutter, Island-class cutter, USCGC Alex Haley, future Heritage-class cutter

After a Spanish reconquest, Colombian independence was secured and the Gran Colombia period began in 1819. The new polity experimented with federalism as the Granadine Confederation (1858) and then the United States of Colombia (1863), before becoming a centralised republic in 1886. With the backing of the US and France, Panama seceded from Colombia in 1903, resulting in Colombia's present borders. Beginning in the 1960s, the country has suffered from an asymmetric low-intensity armed conflict and political violence, both of which escalated in the 1990s. Since 2000, there has been improvement in security, stability, and rule of law, as well as economic growth and development. Colombia is recognized for its healthcare system, being the best healthcare in the Americas according to the World Health Organization and 22nd in the world. Its diversified economy is the third-largest in South America, with macroeconomic stability and favorable long-term growth prospects. The country has one of the widest recognitions of LGBT rights, gender equality, animal rights, and human rights, permitting same-sex adoption, same-sex marriage, legality of abortion, legality of euthanasia, and animal rights protections. Colombia is one of the world's seventeen megadiverse countries; it has the highest level of biodiversity per square mile in the world, and second-highest level overall. Its territory encompasses the Amazon rainforest, highlands, grasslands and deserts.

Thioesters exhibit electrosteric repulsive forces due to amine functional groups and their size, which prevents aggregation. These electrostatic repulsive forces are weakened by counterions in solution, such as Ca2+ found in seawater. Ca2+ ions are naturally found in seawater due to the weathering of calcareous rocks, and allow for dissolution of the oxide-coated particle at low electrolyte concentrations. This leads to the aggregation of silver nanoparticles onto thioesters in seawater. When aggregation occurs, the silver nanoparticles lose microbial toxicity, but have greater exposure in the environment for larger organisms. These effects have not been completely identified, but may be hazardous to an organism's health via biological magnification.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 a natural hormone?

No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.

Why do two versions share one name?

Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.

What is the relationship to GRF(1-29)?

The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Network